<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157129</url>
  </required_header>
  <id_info>
    <org_study_id>HNO-TUM-LT1</org_study_id>
    <nct_id>NCT02157129</nct_id>
  </id_info>
  <brief_title>LipoAerosol© Inhalation After Tracheostomy</brief_title>
  <official_title>LipoAerosol© Inhalation to Maintain the Functional Integrity of the Tracheo-bronchial System in Patients After Tracheostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients after tracheostomy represent a substantial part in the ear nose throat clinic.
      Long-term intubated patients in intensive care units also profit from tracheostomy due to an
      improved respiratory toilet. However, after tracheostomy patients demonstrate shunt
      ventilation bypassing the sinonasal and pharyngeal system. The physiological moistening,
      cleaning and warming of the breathing air fail resulting in a respiratory inflammation.
      Beside a variety of supportive medical devices no general recommendation exists at present.
      Recently, we demonstrated the beneficial application of local phospholipids in Sjoegren's
      syndrome and antineutrophil cytoplasmatic antibody associated sinonasal vasculitis.

      In the current monocentric, two-armed, double-blinded, randomized parallel group study we
      would like to evaluate the beneficial application of LipoAerosol© when compared with standard
      physiologic saline inhalation. LipoAerosol© is a licensed, tradable medical device and will
      be applied as part of its intended use. Liposomal inhalation solution provides moistening,
      cleaning and warming of the upper and lower respiratory tract and supports the natural
      moistening film in airway irritations and diseases.

      Blood parameter (leucocytes and c reactive protein) and tracheobronchial secretion
      (Lymphocyte subpopulation, c reactive protein, lactate dehydrogenase, granulocyte macrophage
      colony stimulating factor, interferon γ, interleukins 10, 12 (p70), 13, 1β, 2, 4, 5, 6, 7, 8,
      tumor necrosis factor α) will be collected 1, 3, and 10 days after tracheostomy. In addition,
      medical examination records the number of suction maneuver (0 points: none; 1 point: 5-10x/d;
      2 points: 10-20x/d; 3 points: &gt;20x/d), flexible-optical assessment of tracheo-bronchial
      redness (0 point: none; 1 point: peristomal; 2 points: tracheal; 3 points: tracheo-bronchial)
      and flexible-optical assessment of mucous congestion (0 point: none; 1 point: fluent; 2
      points: tenacious; 3 points: barky).

      Subjective estimation of the respiratory impairment will be analyzed via visual analogue
      scale (Subjective overall impairment, coughing frequency, breathlessness, mucous congestion,
      color of sputum, consistency of sputum). The study is designed without any additional
      invasive or incriminating clinical examination.

      Aim of the study is to maintain the functional integrity of the tracheo-bronchial system
      after tracheostomy using LipoAerosol© resulting in a general therapeutic recommendation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in tracheal interleukin 6 levels</measure>
    <time_frame>at day 10 after tracheostomy</time_frame>
    <description>Tracheal secretion: Interleukin 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the number of suction maneuver, tracheo-bronchial redness, and mucous congestion</measure>
    <time_frame>at day 10 after tracheostomy</time_frame>
    <description>Changes in the respiratory impairment due to the medical estimation at day 10. The medical estimation includes number of suction maneuver (0 points: none; 1 point: 5-10x/d; 2 points: 10-20x/d; 3 points: &gt;20x/d), flexible-optical assessment of tracheo-bronchial redness (0 point: none; 1 point: peristomal; 2 points: tracheal; 3 points: tracheo-bronchial) and flexible-optical assessment of mucous congestion (0 point: none; 1 point: fluent; 2 points: tenacious; 3 points: barky).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the inflammatory blood and tracheal secretion parameters</measure>
    <time_frame>at day 1, 3, 10 after tracheostomy</time_frame>
    <description>Blood: C reactive protein, leucocytes Tracheal secretion: Lymphocyte subpopulation, c reactive protein, lactate dehydrogenase, granulocyte macrophage colony stimulating factor, interferon γ, interleukins 10, 12 (p70), 13, 1β, 2, 4, 5, 6, 7, 8, tumor necrosis factor α</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in the subjective overall impairment, coughing frequency, breathlessness, mucous congestion, color of sputum, consistency of sputum on the visual analogue scale</measure>
    <time_frame>at day 1, 3, 10 after tracheostomy</time_frame>
    <description>Subjective estimation of the respiratory impairment will be analyzed via visual analogue scale (Subjective overall impairment, coughing frequency, breathlessness, mucous congestion, color of sputum, consistency of sputum).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Other Tracheostomy Complication</condition>
  <arm_group>
    <arm_group_label>LipoAerosol©</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LipoAerosol© inhalation, 5x/d for 30min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Physiologic saline inhalation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physiologic saline inhalation, 5x/d for 30min</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipoAerosol© inhalation</intervention_name>
    <description>LipoAerosol© inhalation, 5x/d for 30min</description>
    <arm_group_label>LipoAerosol©</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologic saline inhalation</intervention_name>
    <description>Physiologic saline inhalation, 5x/d for 30min</description>
    <arm_group_label>Physiologic saline inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≤24h after tracheostomy and regular patient's consent

        Exclusion Criteria:

          -  No regular patient's consent

          -  Known allergy for ingredients

          -  Patients &gt;24h after tracheostomy

          -  Patients with acute or imminent sepsis

          -  Patients with existing bronchopulmonary inflammation

          -  Patients with immunosuppressive therapy

          -  Patients with poorly adjusted pulmonary disease

          -  Patients with chronic respiratory insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Knopf, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HNO, Klinikum rechts der Isar, TU München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HNO, Klinikum rechts der Isar, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Braun A, Steinecker M, Schumacher S, Griese M. Surfactant function in children with chronic airway inflammation. J Appl Physiol (1985). 2004 Dec;97(6):2160-5. Epub 2004 Aug 13.</citation>
    <PMID>15310745</PMID>
  </reference>
  <reference>
    <citation>Hofauer B, Bas M, Strassen U, Matsuba Y, Mansour N, Knopf A. [Liposomal local therapy of sinunasal symptoms in ANCA associated vasculitis]. Laryngorhinootologie. 2014 Jul;93(7):461-6. doi: 10.1055/s-0034-1372588. Epub 2014 Apr 28. German.</citation>
    <PMID>24777579</PMID>
  </reference>
  <reference>
    <citation>Hofauer B, Bas M, Manour N, Knopf A. [Liposomal local therapy as treatment for sicca symptoms in patients with primary Sjögren's syndrome]. HNO. 2013 Nov;61(11):921-7. doi: 10.1007/s00106-013-2736-x. German.</citation>
    <PMID>23868654</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tracheostomy</keyword>
  <keyword>inflammation</keyword>
  <keyword>mucous congestion</keyword>
  <keyword>inhalation therapy</keyword>
  <keyword>phospholipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

